Profound Medical Corp
$ 6.42
2.56%
15 Apr - close price
- Market Cap 227,198,000 USD
- Current Price $ 6.42
- High / Low $ 6.48 / 6.16
- Stock P/E N/A
- Book Value 1.83
- EPS -1.41
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.35 %
- ROE -0.67 %
- 52 Week High 8.95
- 52 Week Low 3.76
About
Profound Medical Corp. The company is headquartered in Mississauga, Canada.
Analyst Target Price
$11.90
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-10 | 2025-11-13 | 2025-08-14 | 2025-05-07 | 2025-03-05 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-02 | 2023-08-09 | 2023-05-10 |
| Reported EPS | -0.27 | 0.26 | -0.52 | -0.36 | -0.2 | -0.38 | -0.28 | -0.26 | -0.42 | -0.26 | -0.35 | -0.32 |
| Estimated EPS | -0.302 | -0.38 | -0.27 | -0.2825 | -0.3225 | -0.3 | -0.29 | -0.3 | -0.32 | -0.33 | -0.34 | -0.34 |
| Surprise | 0.032 | 0.64 | -0.25 | -0.0775 | 0.1225 | -0.08 | 0.01 | 0.04 | -0.1 | 0.07 | -0.01 | 0.02 |
| Surprise Percentage | 10.596% | 168.4211% | -92.5926% | -27.4336% | 37.9845% | -26.6667% | 3.4483% | 13.3333% | -31.25% | 21.2121% | -2.9412% | 5.8824% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.24 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PROF
2026-04-15 16:11:48
This page provides a comprehensive resource for investors to access Profound Med Corp's SEC filings, including annual 10-K reports, quarterly 10-Q earnings, 8-K material events, and insider trading forms. Each filing is accompanied by AI-powered summaries to help users quickly grasp key information. Recent filings highlight operational milestones, financial results, distribution agreements, and equity financings, offering a detailed view of the company's regulatory and financial history.
2026-04-14 14:10:34
Profound Medical Corp. announced that its management will provide a business update at the 2026 Bloom Burton & Co. Healthcare Investor Conference. The presentation is scheduled for Wednesday, April 22, at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre. Following the announcement, shares of Profound Medical Corp. (T.PRN) were trading down $0.01 at $8.50.
2026-04-14 14:10:34
Profound Medical Corp. announced that its management will be presenting a business update at the Bloom Burton & Co. Healthcare Investor Conference on April 22, 2026, at 10:00 a.m. Eastern Time. Following this announcement, the company's shares (T.PRN) were observed trading down by $0.01 at $8.50.
2026-04-14 14:09:15
Profound Medical Corp. announced that its management will present a business update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 22. The presentation will take place at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre. Shares of Profound Medical Corp. were reported to be trading down by $0.01 at $8.50.
2026-04-14 12:09:15
Profound Medical Corp. (TSE:PRN) announced it will present a business update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 22, 2026, in Toronto, with a live webcast available. This presentation aims to increase investor visibility and reinforce Profound's leadership in MRI-guided, incision-free therapies like its TULSA-PRO and Sonalleve platforms. Despite a "Neutral" rating from TipRanks’ AI Analyst, Spark, due to financial performance and technicals, the company seeks to highlight its growth trajectory and role in advancing non-invasive treatment options.
2026-04-14 11:09:15
Profound Medical Corp. announced its participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference. Management will provide a business update on April 22, 2026, at the Metro Toronto Convention Centre, with the presentation also available via live broadcast and archive on the company's website. Profound Medical specializes in AI-powered, MRI-guided, incision-free therapies for diseased tissue, including TULSA-PRO for prostate therapy and Sonalleve for various conditions.
